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Introduction
Breast cancer resistance protein (BCRP) was discovered as a transporter overexpressed in a multidrug-resistant human breast cancer cell line (Doyle et al., 1998) . BCRP has been reported to recognize many anticancer drugs as substrates, such as the cytotoxic drugs capecitabine (Zhang et al., 2015) , methotrexate (Volk et al., 2000) , 7-Ethyl-10-hydroxycamptothecin (SN-38) (Nakatomi et al., 2001) , topotecan (Maliepaard et al., 2001) , mitoxantrone (Miyake et al., 1999) , etoposide (Allen et al., 2003) , and teniposide (Lin et al., 2011) and the molecular-targeted drugs dinaciclib (Cihalova et al., 2015) , flavopiridol (Nakanishi et al., 2003a) , and imatinib (Burger et al., 2004) , and pump these drugs out of cells. Thus, BCRP is known to be involved in multidrug resistance in cancer cells (Nakanishi and Ross, 2012) . Until now, cell lines that overexpress BCRP, such as BCRP-transfected and drug-selected cells, have been used for in vitro studies to investigate BCRP-mediated drug resistance, and it has been reported that the efficacy of anticancer drugs that are substrates for BCRP can be significantly altered by BCRP. For example, MCF-7/AdrVp cells that were selected by the incremental increase of adriamycin in the presence of a P-glycoprotein (P-gp) inhibitor verapamil, and MCF-7 cells stably transfected with BCRP cDNA (MCF-7/BCRP) showed 3,900-fold and 32-fold higher LC 50 of mitoxantrone than that in non-transfected MCF-7 cells, respectively (Doyle et al., 1998) .
However, it is unclear whether the efficacy of anticancer drugs is affected by endogenous BCRP expression, although in pharmaceutical industries, cancer cell line panels consisting of well-defined tumor cell lines without enforced or in vitro induced BCRP expression produced under artificial conditions have been frequently used to screen for anticancer drugs (Shoemaker, 2006; Niu and Wang, 2015) . In drug discovery and development, the current standard procedure often starts with in vitro cell culture-based tests to screen for the efficacy of drugs, but only This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on December 15, 2017 as DOI: 10.1124 at ASPET Journals on January 6, 2018 dmd.aspetjournals.org Downloaded from DMD # 78402 6 approximately 10% of the drugs progress successfully through clinical development (Edmondson et al., 2014) . To increase the success rate of clinical trials, accurate and efficient in vitro screening of anticancer drugs is required. However, currently it remains unclear whether clinically promising drug candidates may be excluded during screening using cancer cell line panels, due to the effect of native BCRP.
The Cancer Cell Line Encyclopedia (CCLE) provides public access to mRNA expression data of approximately 1,000 cancer cell lines (Barretina et al., 2012) . When mRNA expression levels of BCRP were examined in cancer cell lines using the CCLE database, it was found that endogenous BCRP expression varies largely among the cell lines ( Fig. 1 and Supplemental Table   1 ). In the present study, we assessed the impact of BCRP expression on the efficacy of anticancer drugs using several cancer cell lines displaying varied levels of endogenous BCRP expression. In selecting cancer cell lines, BCRP expression levels in cancer cell lines were classified according to the signal intensity (SI) of BCRP; SI>200, High; 100<SI<200, Moderate; and SI<100, Low.
Based on this classification, all five cancer cell lines were selected from pancreatic cancerderived cells to avoid an effect caused by the derivation of tissues. PANC-1 and AsPC-1, HPAF-II and SW 1990, and MIA PaCa-2 were selected as representative cancer cell lines that show high, moderate, and low BCRP expressions, respectively ( Fig. 1 (Matsushima et al., 2005) was subcloned into BamHI and EcoRI sites of the pQCXIN vector (Clontech, Mountain View, CA) to express the target gene along with the neomycin selection marker. Human embryonic kidney 293-T cells were seeded onto collagencoated culture dishes 1 day before the transfection. BCRP-pQCXIN and pPAM3psi, which is an amphotropic retrovirus helper plasmid (Miller and Buttimore, 1986) , were transfected into human embryonic kidney 293-T cells using FuGENE 6 transfection reagent (Roche Life Science, Penzberg, Germany), following the manufacturer's instructions. After 2 days, virus particles were harvested and concentrated. One day before infection, parental MDCKII cells were seeded onto collagen-coated culture plates. The next day, virus particles collected from the cells transfected with BCRP-pQCXIN were added to parental MDCKII cells with 8 μg/mL of polybrene. Infected cells were selected with G418 (250-500 μg/mL) for BCRP expression.
Established cell lines were screened for BCRP activity on the basis of prazosin transport.
TaqMan RT-PCR gene expression analysis and data normalization
Total RNA was isolated using the RNeasy Mini Kit (QIAGEN, Hilden, Germany). The yield of extracted RNA was measured spectrophotometrically at 260 nm. For first-strand cDNA synthesis, 500 ng of total RNA was reverse-transcribed in a final volume of 50 μL following the protocol for the ReverTra Ace qPCR RT Master Mix (TOYOBO, Osaka, Japan). We used 1 μL of cDNA for quantitative real-time PCR using the CFX384 Real-Time PCR Detection System (Bio-Rad, Hercules, CA). The assay identification numbers of inventoried TaqMan RT-PCR analysis of human BCRP, human β-actin, and dog β-actin genes were Hs01053790_m1, This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on December 15, 2017 as DOI: 10.1124 at ASPET Journals on January 6, 2018 dmd.aspetjournals.org Downloaded from DMD # 78402 9 Hs99999903_m1, and Cf03023880_g1, respectively (Applied Biosystems, Carlsbad, CA).
Assays were performed as technical triplicates. Gene expression data were normalized to β-actin as an endogenous control quantified in the same sample. Relative expression differences were calculated using the comparative ΔΔC t method (Livak and Schmittgen, 2001 ).
Western blot analysis
For Western blot analysis, crude membrane fractions were prepared from human pancreatic cancer cell lines and MDCKII cells according to the method described in a previous report (Gant et al., 1991) . The protein concentrations in the fraction were determined using the method of Lowry et al. (1951) , with bovine serum albumin as a standard. The membrane fraction was dissolved in laemmli sample buffer with 10% 2-mercaptoethanol and loaded onto a 10% Bis-Tris gel. Proteins were transferred electrophoretically to a polyvinylidene difluoride membrane using the Trans-Blot Turbo Transfer System (Bio-Rad, Hercules, CA) at 1.3 A for 7 min. The membrane was reacted with mouse monoclonal anti-BCRP antibody, clone BXP-21 (KAMIYA Biomedical Company, Seattle, WA) (1:100), or with rabbit monoclonal anti-β-actin antibody (Cell Signaling Technology, Danvers, MA) (1:200) and then reacted with donkey antimouse-(for BCRP, 1:500) or donkey anti-rabbit (for β-actin, 1:2000) IgG conjugated with horseradish peroxidase to detect proteins using the iBind Flex Western Device (Thermo Fisher Scientific, Waltham, MA). Bands were detected using the ECL Prime Western Blotting Detection Reagent (GE Healthcare, Chicago, IL).
Confocal immunofluorescence microscopy
This article has not been copyedited and formatted. The final version may differ from this version. were performed using a Zeiss C-Apochromat 63x/1.2W Corr water immersion objective. All images were analyzed using the LSM 800 software.
Cell proliferation assay
Cells were seeded onto 96-well plates at a density of 1500 cells/well. On the next day, anticancer drugs were added at different concentrations in the absence or presence of 10 μM of fumitremorgin C (FTC). After a 72-h incubation, the cell density was determined using the sulforhodamine B assay in accordance with reported procedures (Vichai and Kirtikara, 2006 
mRNA quantification after treatment with anticancer drugs
Cells were seeded into 24-well plates at a density of 8900 cells/well. The next day, the cells were exposed to anticancer drugs at the indicated concentrations for 72 h. RNA isolation, reverse transcription, and quantitative real-time PCR were performed as described in the previous section.
Data analysis
The percentage of control cell growth was calculated using the following equation: 
where x is the drug concentration, E min and E max are the percentages of cell growth when x is infinity and 0, respectively, and H is the slope factor.
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Subcellular localization of the BCRP protein in pancreatic cancer cell lines and MDCKII cells
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2B ), the subcellular localization of the BCRP protein was examined in these cells using confocal immunofluorescence microscopic analysis. The Na + /K + -ATPase protein was co-stained with BCRP as a marker of the plasma membrane. In MDCKII-BCRP cells, the BCRP protein was expressed not only in the plasma membrane but also throughout the cells, and a stronger signal could be observed in the plasma membrane than inside the cells (Fig. 3 ). The BCRP protein was not detected in MDCKII-MOCK cells (Fig. 3 ). In PANC-1 and AsPC-1 cells, BCRP was expressed mainly in the plasma membranes ( Fig. 3 ).
EC 50 values of anticancer drugs in the absence and presence of FTC in MDCKII cells
Nine anticancer drugs that are substrates of BCRP and have different modes of action were selected (Table 1) µM. Although RRs of SN-38 (3.1) and dinaciclib (2.1) were >2, RRs of most anticancer drugs were <2 in MDCKII-MOCK cells in which BCRP was not expressed (Table 1) . Therefore, RR >2 was considered to be significant effect by BCRP inhibition. RR of methotrexate was <2, and calculated. RRs of SN-38, topotecan, and mitoxantrone were 18, 11, and 3.7, respectively, in PANC-1 and 3.5, 3.9, and 3.0, respectively, in AsPC-1 (Table 2) . RRs of dinaciclib and flavopiridol in PANC-1 and AsPC-1 cells were <2. In HPAF-II, SW 1990, and MIA PaCa-2 cells, none of these five drugs showed RRs >2, except SN-38 in MIA PaCa-2 cells (Table 2) .
Relationship between RRs of anticancer drugs and BCRP expression in pancreatic cancer cell lines and MDCKII-BCRP cells
This article has not been copyedited and formatted. The final version may differ from this version. were within 2-fold. In MIA PaCa-2 cells, a concentration-dependent, >10-fold increase in BCRP mRNA expression was observed after treatment with SN-38, topotecan, and mitoxantrone, with increases in expression at higher concentrations of 15, 17, and 20-folds, respectively (Table 3) .
Discussion
In CCLE, 28% pancreatic cancer cell lines (12 of 43) express BCRP at high levels, and the rest of them show moderate or low BCRP expression based on the classification of SI (SI>200, High; 100<SI<200, Moderate; and SI<100, Low) (Fig. 1) . In the present study, we (Table 2) . Overall, RRs of anticancer drugs became larger with an increase in BCRP mRNA expression (Fig. 4) . Because all cell lines used in this study were derived from pancreatic cancer, further investigations are required to evaluate whether the findings are true in cell lines derived from other cancer types.
Because it is well recognized that mRNA expression is a surrogate of protein expression and that transporters are functional when expressed in plasma membranes of cells, a relationship between mRNA ( Fig. 2A) , protein expression ( Fig. 2B and Supplemental Fig. 1A) , and protein subcellular localization (Fig. 3) (Mohrmann et al., 2005) . In fact, RRs of SN-38, topotecan, and mitoxantrone were >2
in AsPC-1 cells, which suggested that BCRP expressed in AsPC-1 cells was functional.
BCRP mRNA expression increased in the MIA PaCa-2 cells treated with anticancer drugs (Table 3) ; however, the increased expression levels in these cells still remained the lowest in rank order among the five pancreatic cancer cell lines used in this study. Thus, no changes in BCRP mRNA expression occurred after incubation with anticancer drugs, which affected RRs of these drugs and interpretation of the results shown in Figure 4 . Because the number of cell lines used in this study was limited, further investigations are required to identify any cancer cell lines that show increased BCRP expression after treatment with anticancer drugs, sufficient to alter RRs.
As shown in Figure 4 , the overall RRs of anticancer drugs could be explained by BCRP mRNA expression levels. However, in the present study, RR of SN-38 was 2.1 in MIA PaCa-2 cells, which was of borderline significance of BCRP effect despite low BCRP expression (Table   2 ), and such a high RR value of SN-38 was also observed in MDCKII-MOCK cells (3.1) ( Table   1 ). SN-38 was reported to be a substrate of not only BCRP but also other efflux transporters, such as P-gp, multidrug-resistance protein 1, and multidrug-resistance protein 2 (Kwak et al.,
2012). Because the mRNA expression level of P-gp in MIA PaCa-2 cells was low, endogenous
This article has not been copyedited and formatted. The final version may differ from this version. Transcellular transport experiments of SN-38, topotecan, mitoxantrone, and flavopiridol using MDCKII-MOCK and MDCKII-BCRP cells have been reported (Xiao et al., 2006; Zhou et al., 2009) , and the corrected efflux ratio, which is the normalized ratio of basal-to-apical versus apical-to-basal permeability in MDCKII-MOCK cell monolayers with respect to that in MDCKII-BCRP cell monolayers, of these four drugs was comparable (7.6~8.4 in SN-38, 2.6~5.4
in topotecan, 4.5~6.1 in mitoxantrone, and 6.0 in flavopiridol). However, our study showed that RRs of topoisomerase I inhibitors (SN-38 and topotecan) were much larger than those of mitoxantrone and flavopiridol in MDCKII-BCRP cells (Table 1) . The magnitude of RRs may not be directly explained by the efflux ratio alone, which is an indicator of the importance of efflux transporters in transporting drugs across the cell membrane (Giacomini et al., 2010) . Namely, there may be a determinant rather than the active efflux of anticancer drugs by BCRP. For example, the anticancer efficacy of drugs depends on their chemical structure within the tumor microenvironment. SN-38 and topotecan are pharmacologically active in the lactone form, but most of them are in the inactive carboxylate form at physiological pH (Oguma, 2001) . With reference to the transport of lactone and carboxylate forms of SN-38, we have recently shown that they are similarly transported by another type of transporter, organic anion-transporting polypeptide 2B1 (Fujita et al., 2016) . However, the same result may not be directly applicable to BCRP-mediated transport, and the efflux ratio of the lactone forms of these drugs separately evaluated from their carboxylate forms will be required.
BCRP mRNA expression in pancreatic cancer cell lines used in this study was compared to that in cancer biopsies available from the Expression Project for Oncology (expO) (accession Table 2 ). However, this does not necessarily mean that drug resistance caused by BCRP-mediated efflux in cancer tissues can be ignored. Although BCRP mRNA expression increased in MIA PaCa-2 cells exposed to anticancer drugs (Table 3 ) and in vivo, leukemic blasts from patients with acute leukemia showed a significant increase in BCRP mRNA expression after in vivo flavopiridol exposure (Nakanishi et al., 2003b) , more than 90% of the cancer biopsies shown in Figure 5 were from patients who did not receive any chemotherapy before surgical resection, according to clinically annotated expO information (accession number:
GSE2109; Gene Expression Omnibus). Therefore, it should be kept in mind that BCRP expression levels in cancer tissues after chemotherapy might be different from those shown in Figure 5 . In addition, cancer tissues consist of heterogeneous cells, and BCRP is reported to be highly expressed in cancer stem cells that are considered responsible for the tumorigenic process (An and Ongkeko, 2009; Natarajan et al., 2012) . However, BCRP expression levels in cancer biopsies shown in Figure 5 represent an average across heterogeneous cells, including cancer stem cells and other types of cells.
In conclusion, our results suggest that the in vitro efficacy of anticancer drugs on cell proliferation was significantly affected by BCRP in pancreatic cancer cell lines abundantly Table 2 .
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